Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BTMD NASDAQ:PLRX NASDAQ:QCLS NASDAQ:RLYB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBTMDbiote$2.34-0.8%$1.96$1.27▼$4.75$87.94M1.65226,355 shs76,976 shsPLRXPliant Therapeutics$1.15-1.7%$1.24$1.09▼$1.95$71.21M1.19513,271 shs409,103 shsQCLSMymd Pharmaceuticals$3.71-2.1%$0.00$2.50▼$33.56$15.46M2.17662,648 shs496,044 shsRLYBRallybio$15.95-1.5%$11.55$2.40▼$17.57$84.50M-0.8888,601 shs35,073 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBTMDbiote-0.85%+17.00%+6.36%+24.47%-33.90%PLRXPliant Therapeutics-1.71%-8.73%-6.50%-13.53%-30.72%QCLSMymd Pharmaceuticals-2.11%-15.10%+370,999,900.00%+370,999,900.00%+370,999,900.00%RLYBRallybio-1.54%+10.30%+9.55%+46.20%+430.25%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBTMDbiote$2.34-0.8%$1.96$1.27▼$4.75$87.94M1.65226,355 shs76,976 shsPLRXPliant Therapeutics$1.15-1.7%$1.24$1.09▼$1.95$71.21M1.19513,271 shs409,103 shsQCLSMymd Pharmaceuticals$3.71-2.1%$0.00$2.50▼$33.56$15.46M2.17662,648 shs496,044 shsRLYBRallybio$15.95-1.5%$11.55$2.40▼$17.57$84.50M-0.8888,601 shs35,073 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBTMDbiote-0.85%+17.00%+6.36%+24.47%-33.90%PLRXPliant Therapeutics-1.71%-8.73%-6.50%-13.53%-30.72%QCLSMymd Pharmaceuticals-2.11%-15.10%+370,999,900.00%+370,999,900.00%+370,999,900.00%RLYBRallybio-1.54%+10.30%+9.55%+46.20%+430.25%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBTMDbiote 2.25Hold$2.7517.52% UpsidePLRXPliant Therapeutics 1.80Reduce$3.00160.87% UpsideQCLSMymd Pharmaceuticals 1.00SellN/AN/ARLYBRallybio 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest QCLS, PLRX, RLYB, and BTMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2026BTMDbiote Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D) ➝ Sell (D+)5/13/2026BTMDbiote Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D+) ➝ Sell (D)5/13/2026QCLSMymd Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageSell (E+)5/8/2026RLYBRallybio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026PLRXPliant Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/16/2026BTMDbiote Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$5.00 ➝ $4.003/13/2026PLRXPliant Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetHold$4.00 ➝ $3.003/12/2026BTMDbiote National Bank FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$2.503/12/2026BTMDbiote TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$3.00 ➝ $2.503/12/2026PLRXPliant Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$4.00 ➝ $3.003/12/2026BTMDbiote B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$3.00 ➝ $2.00(Data available from 6/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBTMDbiote$192.22M0.46$0.58 per share4.03($1.40) per share-1.67PLRXPliant Therapeutics$1.58M45.07N/AN/A$2.95 per share0.39QCLSMymd PharmaceuticalsN/AN/AN/AN/A$5.19 per shareN/ARLYBRallybio$860K98.30N/AN/A$10.98 per share1.45Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBTMDbiote$27.05M$0.445.324.42N/A8.29%-25.72%15.12%8/5/2026 (Estimated)PLRXPliant Therapeutics-$149.34M-$1.84N/AN/AN/AN/A-58.11%-44.37%8/6/2026 (Estimated)QCLSMymd Pharmaceuticals-$11.63M-$20.69N/AN/AN/AN/A-76.40%-35.10%N/ARLYBRallybio-$8.98M-$4.34N/AN/AN/A-911.07%-55.79%-51.48%8/6/2026 (Estimated)Latest QCLS, PLRX, RLYB, and BTMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026QCLSMymd PharmaceuticalsN/A-$0.19N/A-$0.19N/AN/A5/13/2026Q1 2026RLYBRallybio-$1.20-$1.46-$0.26-$1.46$0.21 million$0.21 million5/11/2026Q1 2026PLRXPliant Therapeutics-$0.36-$0.32+$0.04-$0.32N/AN/A5/6/2026Q1 2026BTMDbiote$0.09$0.06-$0.03$0.06$46.02 million$44.94 million4/15/2026Q4 2025QCLSMymd PharmaceuticalsN/A$6.11N/A$6.11N/AN/A3/16/2026Q4 2025RLYBRallybio-$1.04-$1.03+$0.01-$1.03$0.10 million$0.22 million3/11/2026Q4 2025BTMDbiote$0.05$0.06+$0.01$0.06$45.79 million$46.41 million3/11/2026Q4 2025PLRXPliant Therapeutics-$0.44-$0.35+$0.09-$0.38N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBTMDbioteN/AN/AN/AN/AN/APLRXPliant TherapeuticsN/AN/AN/AN/AN/AQCLSMymd PharmaceuticalsN/AN/AN/AN/AN/ARLYBRallybioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBTMDbioteN/A1.290.58PLRXPliant TherapeuticsN/A16.8916.89QCLSMymd PharmaceuticalsN/A3.723.72RLYBRallybioN/A12.9212.92Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBTMDbiote21.68%PLRXPliant Therapeutics97.30%QCLSMymd Pharmaceuticals9.64%RLYBRallybio90.34%Insider OwnershipCompanyInsider OwnershipBTMDbiote32.40%PLRXPliant Therapeutics8.00%QCLSMymd Pharmaceuticals0.86%RLYBRallybio10.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBTMDbiote19437.58 million25.41 millionNot OptionablePLRXPliant Therapeutics9061.92 million56.97 millionOptionableQCLSMymd Pharmaceuticals64.17 million4.13 millionN/ARLYBRallybio405.30 million4.75 millionNot OptionableQCLS, PLRX, RLYB, and BTMD HeadlinesRecent News About These CompaniesRallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYBJune 2, 2026 | businesswire.comRallybio, Avenzo agree oncology reverse merger backed by $215 million financingJune 2, 2026 | thepharmaletter.comTRLYB Stock Hits 2-Year Highs After Unveiling Merger With Avenzo – How Much Of The New Company Will Rallybio Shareholders Own?June 1, 2026 | finance.yahoo.comRLYB Stock Alert: Halper Sadeh LLC is Investigating Whether Rallybio Corporation is Obtaining a Fair Price for its ShareholdersJune 1, 2026 | businesswire.comRallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private PlacementJune 1, 2026 | businesswire.comRallybio CorporationMay 22, 2026 | edition.cnn.comRallybio (NASDAQ:RLYB) Major Shareholder Adar1 Capital Management, Llc Buys 6,009 SharesMay 21, 2026 | insidertrades.comInsider Buying: Rallybio (NASDAQ:RLYB) Major Shareholder Acquires 6,009 Shares of StockMay 20, 2026 | marketbeat.comInsider Buying: Rallybio (NASDAQ:RLYB) Major Shareholder Buys 10,200 Shares of StockMay 20, 2026 | marketbeat.comAdar1 Capital Management buys $1.11m of Rallybio (RLYB) stockMay 16, 2026 | investing.comInsider Buying: Rallybio (NASDAQ:RLYB) Major Shareholder Purchases 79,259 Shares of StockMay 16, 2026 | insidertrades.comRallybio (NASDAQ:RLYB) Major Shareholder Adar1 Capital Management, Llc Acquires 800 SharesMay 14, 2026 | insidertrades.comRallybio (NASDAQ:RLYB) Major Shareholder Adar1 Capital Management, Llc Purchases 35,101 SharesMay 7, 2026 | insidertrades.comRallybio Receives Termination Fee After Candid Deal CollapseMay 4, 2026 | tipranks.comRallybio CMO Departs Amid Pending Candid Therapeutics MergerMarch 31, 2026 | tipranks.comCandid lists via Rallybio reverse merger, adds $505m financingMarch 5, 2026 | thepharmaletter.comTRallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYBMarch 4, 2026 | businesswire.comRallybio Corp.March 3, 2026 | marketwatch.comRallybio Corporation and Candid Therapeutics Announce Merger AgreementMarch 2, 2026 | finance.yahoo.comRallybio Corporation (RLYB) M&A Call Prepared Remarks TranscriptMarch 2, 2026 | seekingalpha.comRallybio to Merge with Candid Therapeutics in All-Stock DealMarch 2, 2026 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeQCLS, PLRX, RLYB, and BTMD Company Descriptionsbiote NASDAQ:BTMD$2.34 -0.02 (-0.85%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$2.34 0.00 (0.00%) As of 06/5/2026 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.Pliant Therapeutics NASDAQ:PLRX$1.15 -0.02 (-1.71%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$1.15 0.00 (0.00%) As of 06/5/2026 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.Mymd Pharmaceuticals NASDAQ:QCLS$3.71 -0.08 (-2.11%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$3.68 -0.04 (-0.94%) As of 06/5/2026 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.TNF Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to treat diseases and disorders marked by acute or chronic inflammation. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.Rallybio NASDAQ:RLYB$15.95 -0.25 (-1.54%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$15.92 -0.02 (-0.16%) As of 06/5/2026 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/01 - 06/05 Samsara Just Answered The AI Question—Is Wall Street Ready To Listen? A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? IREN's 800MW Bet Flips the AI Power Switch Buy the Dip? Broadcom's AI Moat Is Wider Than Ever CrowdStrike Earnings Beat Sparks Selloff—Buy the Dip? The Market Has Ollie’s Bargain Outlet Completely Wrong Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
